STOCK AND ASSET PURCHASE AGREEMENT by and among Novartis Pharma AG, Novartis Finance Corporation, Bausch + Lomb Ireland Limited and Bausch + Lomb Corporation, solely for the purposes of Article 1 and Section 10.17 Dated as of June 30, 2023Stock and Asset Purchase Agreement • July 7th, 2023 • Bausch & Lomb Corp • Ophthalmic goods • Delaware
This Stock and Asset Purchase Agreement (this “Agreement”) is made and executed as of June 30, 2023, by and among Novartis Pharma AG, a company incorporated under the laws of Switzerland (“Swiss Seller”), Novartis Finance Corporation, a New York corporation (“US Seller” and, collectively with Swiss Seller, “Seller”), Bausch + Lomb Ireland Limited, a company organized under the laws of the Republic of Ireland (“Buyer”), and, solely for the purposes of Article 1 and Section 10.17, Bausch + Lomb Corporation, a Canadian corporation (“Parent”). Seller, Buyer and, solely with respect to Article 1 and Section 10.17, Parent, are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
